Cellular uptake and in vitro antitumor efficacy of composite liposomes for neutron capture therapy

详细信息    查看全文

• 作者：Tanja Peters ; Catrin Grunewald ; Matthias Blaickner ; Markus Ziegner…
• 关键词：Gadolinium ; Liposomes ; Drug uptake ; Neutron capture therapy ; Glioma ; Theranostic
• 刊名：Radiation Oncology
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：10
• 期：1
• 全文大小：1,326 KB
• 参考文献：1. Stasio, G, Casalbore, P, Pallini, R, Gilbert, B, Sanita, F, Ciotti, MT (2001) Gadolinium in human glioblastoma cells for gadolinium neutron capture therapy. Cancer Res 61: pp. 4272-7
  2. Miladi, I, Duc, G, Kryza, D, Berniard, A, Mowat, P, Roux, S (2013) Biodistribution of ultra small gadolinium-based nanoparticles as theranostic agent: Application to brain tumors. J Biomater Appl 28: pp. 385-94 CrossRef
  3. Martin, RF, D'Cunha, G, Pardee, M, Allen, BJ (1989) Induction of DNA Double-Strand Breaks by 157Gd Neutron Capture. Pigment Cell Research 2: pp. 330-2 CrossRef
  4. Shih, JL, Brugger, RM (1992) Gadolinium as a neutron capture therapy agent. Med Phys 19: pp. 733-44 CrossRef
  5. Gonzalvez, F, Gottlieb, E (2007) Cardiolipin: setting the beat of apoptosis. Apoptosis 12: pp. 877-85 CrossRef
  6. Zuhorn, IS, Hoekstra, D (2002) On the mechanism of cationic amphiphile-mediated transfection. To fuse or not to fuse: is that the question?. J Membr Biol 189: pp. 167-79 CrossRef
  7. Simoes, S, Slepushkin, V, Duzgunes, N, Pedroso de Lima, MC (2001) On the mechanisms of internalization and intracellular delivery mediated by pH-sensitive liposomes. Biochim Biophys Acta 1515: pp. 23-37 CrossRef
  8. Simoes, S, Moreira, JN, Fonseca, C, Duzgunes, N, Lima, MC (2004) On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 56: pp. 947-65 CrossRef
  9. Lima MC, P, Simoes, S, Pires, P, Faneca, H, Duzgunes, N (2001) Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Deliv Rev 47: pp. 277-94 CrossRef
  10. Miller, CR, Bondurant, B, McLean, SD, McGovern, KA, O'Brien, DF (1998) Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37: pp. 12875-83 CrossRef
  11. Low, PS, Kularatne, SA (2009) Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 13: pp. 256-62 CrossRef
  12. Sanchez-del-Campo, L, Montenegro, MF, Cabezas-Herrera, J, Rodriguez-Lopez, JN (2009) The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate. Pigment Cell Melanoma Res 22: pp. 588-600 CrossRef
  13. Saul, JM, Annapragada, A, Natarajan, JV, Bellamkonda, RV (2003) Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. Journal of Controlled Release 92: pp. 49-67 CrossRef
  14. Parker, N, Turk, MJ, Westrick, E, Lewis, JD, Low, PS, Leamon, CP (2005) Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 338: pp. 284-93 CrossRef
  15. Matherly, LH, Hou, Z, Deng, Y (2007) Human reduced folate carrier: translation of basic biology to cancer etiology and therapy. Cancer Metastasis Rev 26: pp. 111-28 CrossRef
  16. Ziegner, M, Schmitz, T, Khan, R, Blaickner, M, Palmans, H, Sharpe, P (2014) Confirmation of a realistic reactor model for BNCT dosimetry at the TRIGA Mainz. Med Phys 41: pp. 111706 CrossRef
  17. Schmitz, T, Bassler, N, Blaickner, M, Ziegner, M, Hsiao, MC, Liu
• 刊物主题：Oncology; Radiotherapy;
• 出版者：BioMed Central
• ISSN：1748-717X

文摘

Background Neutron capture therapy for glioblastoma has focused mainly on the use of 10B as neutron capture isotope. However, 157Gd offers several advantages over boron, such as higher cross section for thermal neutrons and the possibility to perform magnetic resonance imaging during neutron irradiation, thereby combining therapy and diagnostics. We have developed different liposomal formulations of gadolinium-DTPA (Magnevist?) for application in neutron capture therapy of glioblastoma. The formulations were characterized physicochemically and tested in vitro in a glioma cell model for their effectiveness. Methods Liposomes entrapping gadolinium-DTPA as neutron capture agent were manufactured via lipid/film-extrusion method and characterized with regard to size, entrapment efficiency and in vitro release. For neutron irradiation, F98 and LN229 glioma cells were incubated with the newly developed liposomes and subsequently irradiated at the thermal column of the TRIGA reactor in Mainz. The dose rate derived from neutron irradiation with 157Gd as neutron capturing agent was calculated via Monte Carlo simulations and set in relation to the respective cell survival. Results The liposomal Gd-DTPA reduced cell survival of F98 and LN229 cells significantly. Differences in liposomal composition of the formulations led to distinctly different outcome in cell survival. The amount of cellular Gd was not at all times proportional to cell survival, indicating that intracellular deposition of formulated Gd has a major influence on cell survival. The majority of the dose contribution arises from photon cross irradiation compared to a very small Gd-related dose. Conclusions Liposomal gadolinium formulations represent a promising approach for neutron capture therapy of glioblastoma cells. The liposome composition determines the uptake and the survival of cells following radiation, presumably due to different uptake pathways of liposomes and intracellular deposition of gadolinium-DTPA. Due to the small range of the Auger and conversion electrons produced in 157Gd capture, the proximity of Gd-atoms to cellular DNA is a crucial factor for infliction of lethal damage. Furthermore, Gd-containing liposomes may be used as MRI contrast agents for diagnostic purposes and surveillance of tumor targeting, thus enabling a theranostic approach for tumor therapy.